Log In
Print
BCIQ
Print
Print this Print this
 

ChemoFx Assay

  Manage Alerts
Collapse Summary General Information
Company Helomics Corp.
DescriptionEx vivo assay that uses a core biopsy to predict sensitivity and resistance of a patient's solid tumor to various chemotherapeutic agents
Molecular Target Not applicable
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsAssess the likelihood of response to various cancer drugs in patients with locally advanced stage II and III breast cancer; Predict response of endometrial cancer to chemotherapy; Predict response of recurrent ovarian cancer to chemotherapy; Predict response to first-line ovarian cancer treatment; Predict the effectiveness of Erbitux cetuximab on colorectal cancer cells
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today